NeoPharm Co

NeoPharm Co ROA

The Return on Assets (ROA) of NeoPharm Co (092730.KQ) as of Nov 20, 2026 is 12.77 %. In the previous year, Return on Assets (ROA) was 11.99 % — a change of 6.58% (higher).

ROA

12.77 %

YoY

6.58%

Last updated:

In 2025, NeoPharm Co's return on assets (ROA) was 12.77 %, a 6.58% increase from the 11.99 % ROA in the previous year.

The NeoPharm Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
21.08 KRW
Jan 1, 2019
15.68 KRW
Jan 1, 2020
13.63 KRW
Jan 1, 2021
12.35 KRW
Jan 1, 2022
10.96 KRW
Jan 1, 2023
13.08 KRW
Jan 1, 2024
11.99 KRW
Jan 1, 2025
12.77 KRW
The NeoPharm Co ROA history
YEARROAYoY
12.77 %+6.58%
11.99 %-8.37%
13.08 %+19.34%
10.96 %-11.26%
12.35 %-9.41%
13.63 %-13.04%
15.68 %-25.60%
21.08 %+3.37%
20.39 %+22.47%
16.65 %+97.44%
8.43 %+17.66%
7.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoPharm Co Stock analysis

What does NeoPharm Co do? NeoPharm Co., Ltd. generates revenue through the development, manufacture, and sale of cosmetics, medical, and health products under its own brand names. The company sells ATOPALM products, which include daily care, intensive care, special care, and baby care items, as well as Derma:B products such as foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, BB creams, sun protectors, white watering serums, and anti-aging eye creams. ZEROID products, featuring creams and lotions for skin barrier recovery and hypoallergenic foaming cleansers for atopic and sensitive skin, also contribute to sales. Additionally, NeoPharm provides original equipment manufacturing (OEM) services for skin drugs, supplying these to other companies. The primary buyers of NeoPharm's products are consumers seeking skincare solutions for daily use, sensitive skin conditions, and medical-grade treatments. ATOPALM targets general skincare and baby care markets, while Derma:B appeals to users looking for comprehensive skincare routines including anti-aging and sun protection. ZEROID focuses on individuals with atopic or sensitive skin requiring gentle, hypoallergenic products. OEM services are purchased by other pharmaceutical companies needing skin drug manufacturing capabilities. NeoPharm's product portfolio is structured around four key brands: ATOPALM, Derma:B, ZEROID, and OEM services. ATOPALM and Derma:B cater to broad consumer segments in the cosmetics and skincare industry, with Derma:B offering a wide range of products for various skin concerns. ZEROID serves a specialized segment for sensitive skin care, and OEM services target business-to-business clients in the pharmaceutical sector. The company's revenue streams are thus diversified across consumer-facing brands and B2B manufacturing contracts. NeoPharm Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding NeoPharm Co's Return on Assets (ROA)

NeoPharm Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing NeoPharm Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider NeoPharm Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in NeoPharm Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about NeoPharm Co stock

Return on Assets (ROA) of NeoPharm Co is 12.77 % in 2025.

Return on Assets (ROA) of NeoPharm Co changed from 11.99 % to 12.77 %, representing a 6.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) NeoPharm Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s NeoPharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NeoPharm Co

All Key Metrics — NeoPharm Co